cash flow reconciliationreview2024-12-31
Operating, investing and financing flows differ from the reported change in cash by 1695000, beyond tolerance 1000000.
Revenue
$334.98M
Fiscal year ended 2026-06-30Operating income
-$129.12M
Fiscal year ended 2026-06-30Free cash flow
-$69.54M
Fiscal year ended 2026-06-30Guardant Health, Inc. (GH) reported revenue of $334.98M and net income of -$120.14M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Guardant Health, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $334.98M | $301.66M | $281.27M | $265.20M | $232.09M | $203.47M | $201.81M | $191.48M | $177.24M | $168.49M |
| Cost of revenue | $115.95M | $104.92M | $99.49M | $93.59M | $81.20M | $74.72M | $77.59M | $74.49M | $72.42M | $65.30M |
| Gross profit | $219.03M | $196.75M | $181.77M | $171.61M | $150.88M | $128.75M | $124.22M | $116.99M | $104.81M | $103.20M |
| Operating income | -$129.12M | -$121.35M | -$120.80M | -$98.99M | -$106.41M | -$111.04M | -$125.96M | -$117.33M | -$100.62M | -$99.68M |
| Net income | -$120.14M | -$112.08M | -$128.49M | -$92.72M | -$99.90M | -$95.16M | -$111.01M | -$107.75M | -$102.63M | -$114.98M |
| Research & development | $96.53M | $91.04M | $98.26M | $89.96M | $87.45M | $88.52M | $93.54M | $87.31M | $83.10M | $83.80M |
| Weighted-average diluted shares | shares 132.87M | shares 131.27M | Unavailable | shares 124.81M | shares 124.11M | shares 123.87M | Unavailable | shares 123.05M | shares 122.45M | shares 121.71M |
| Pretax income | -$119.96M | -$111.70M | -$130.22M | -$92.59M | -$99.86M | -$94.87M | -$110.29M | -$107.72M | -$102.50M | -$114.58M |
| Income tax expense | $185.00K | $372.00K | -$1.73M | $136.00K | $38.00K | $290.00K | $716.00K | $30.00K | $133.00K | $405.00K |
| Diluted EPS | $-0.90 | $-0.85 | Unavailable | $-0.74 | $-0.80 | $-0.77 | Unavailable | $-0.88 | $-0.84 | $-0.94 |
| Selling, general & administrative | $251.61M | $227.06M | $204.32M | $180.64M | $169.85M | $151.27M | $156.64M | $147.01M | $122.33M | $119.08M |
| General & administrative | $61.66M | $57.93M | $60.93M | $53.27M | $50.26M | $46.95M | $51.88M | $49.13M | $40.46M | $38.65M |
| Selling & marketing | $189.95M | $169.13M | $143.38M | $127.38M | $119.59M | $104.32M | $104.76M | $97.88M | $81.87M | $80.42M |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.05B | $989.29M | $378.20M | $580.01M | $629.14M | $698.57M | $525.54M | $585.02M | $933.69M | $1.03B |
| Total assets | $1.91B | $1.92B | $2.01B | $1.28B | $1.33B | $1.34B | $1.49B | $1.54B | $1.61B | $1.70B |
| Current assets | $1.36B | $1.37B | $1.47B | $828.88M | $883.43M | $927.03M | $1.06B | $1.23B | $1.29B | $1.31B |
| Total liabilities | $2.14B | $2.10B | $2.11B | $1.63B | $1.64B | $1.60B | $1.63B | $1.60B | $1.61B | $1.64B |
| Current liabilities | $338.96M | $292.14M | $302.73M | $236.92M | $238.43M | $225.75M | $225.58M | $197.34M | $201.57M | $220.01M |
| Total equity incl. NCI | -$222.87M | -$181.07M | -$99.31M | -$354.47M | -$305.48M | -$250.79M | -$139.65M | -$60.10M | -$1.61M | $68.28M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $105.46M | $83.85M | $85.88M | $90.49M | $84.06M | $77.26M | $71.08M | $72.30M | $66.98M | $62.99M |
| Accounts receivable | $144.25M | $137.40M | $137.85M | $115.58M | $130.25M | $115.43M | $110.25M | $88.46M | $100.52M | $84.56M |
| Goodwill | $77.26M | $77.26M | $77.26M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M | $3.29M |
| Long-term debt | $1.50B | $1.50B | $1.50B | $1.11B | $1.12B | $1.12B | $1.14B | Unavailable | Unavailable | Unavailable |
| Accounts payable | $93.51M | $75.03M | $54.44M | $20.14M | $44.80M | $49.77M | $38.55M | $15.47M | $42.45M | $37.60M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$57.78M | -$65.62M | -$26.37M | -$35.41M | -$60.28M | -$62.69M | -$64.51M | -$51.06M | -$94.00M | -$30.28M |
| Capital expenditures | $11.76M | $5.58M | $27.85M | $10.35M | $5.65M | $4.46M | $18.88M | $4.20M | $5.08M | $6.93M |
| Investing cash flow | $101.47M | $699.42M | -$905.07M | -$14.35M | -$10.65M | $302.86M | $10.53M | -$294.83M | -$5.08M | $28.07M |
| Financing cash flow | $23.01M | -$21.58M | $732.03M | $4.33M | $1.62M | -$66.85M | -$2.94M | -$2.88M | $5.90M | -$1.07M |
| Net change in cash | $66.30M | $612.02M | -$200.10M | -$45.96M | -$68.37M | $174.10M | -$58.61M | -$346.87M | -$94.02M | -$4.43M |
| Stock-based compensation | $57.72M | $47.61M | $43.19M | $42.81M | $42.46M | $37.76M | $36.37M | $49.77M | $27.24M | $27.04M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | $0 | $0 | $0 | $0 | $0 | $45.01M | $0 | $0 | $0 | $0 |
| Depreciation & amortization | $9.56M | $9.44M | $10.05M | $9.41M | $10.04M | $10.24M | $10.45M | $10.60M | $10.62M | $10.71M |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | -$69.54M | -$71.20M | -$54.22M | -$45.76M | -$65.93M | -$67.15M | -$83.39M | -$55.26M | -$99.08M | -$37.22M |
| Gross margin | 65.4% | 65.2% | 64.6% | 64.7% | 65.0% | 63.3% | 61.6% | 61.1% | 59.1% | 61.2% |
| Operating margin | -38.5% | -40.2% | -43.0% | -37.3% | -45.9% | -54.6% | -62.4% | -61.3% | -56.8% | -59.2% |
| FCF margin | -20.8% | -23.6% | -19.3% | -17.3% | -28.4% | -33.0% | -41.3% | -28.9% | -55.9% | -22.1% |
| SBC / revenue | 17.2% | 15.8% | 15.4% | 16.1% | 18.3% | 18.6% | 18.0% | 26.0% | 15.4% | 16.0% |
| Current ratio | 4.03x | 4.68x | 4.84x | 3.50x | 3.71x | 4.11x | 4.68x | 6.22x | 6.40x | 5.95x |
| Revenue YoY growth | 44.3% | 48.3% | 39.4% | 38.5% | 30.9% | 20.8% | 30.2% | 33.9% | 29.2% | 30.9% |
| Net margin | -35.9% | -37.2% | -45.7% | -35.0% | -43.0% | -46.8% | -55.0% | -56.3% | -57.9% | -68.2% |
| R&D / revenue | 28.8% | 30.2% | 34.9% | 33.9% | 37.7% | 43.5% | 46.4% | 45.6% | 46.9% | 49.7% |
| CapEx / revenue | 3.5% | 1.8% | 9.9% | 3.9% | 2.4% | 2.2% | 9.4% | 2.2% | 2.9% | 4.1% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GH in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-04-30View SEC filing
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
cash flow reconciliationreview2022-12-31
Operating, investing and financing flows differ from the reported change in cash by 1140000, beyond tolerance 1000000.